Systematic Reviews
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8212-8223
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8212
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Retrieval from SEER database and literature. SEER: Surveillance Epidemiology and End Results; WHO: World Health Organization; GB-NEC: Gallbladder neroendocrine carcinoma; GB-ADC: Gallbladder adenocarcinoma.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Neuroendocrine carcinoma of gallbladder under magnetic resonance imaging and pathological section. A: Gallbladder neuroendocrine carcinoma invading the liver magnetic resonance imaging T2 AX FAST; B: Poorly differentiated neuroendocrine carcinoma of the gallbladder, with some high-grade intraepithelial neoplasia of the gallbladder epithelium, canceration (< 5%).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Overall survival of GB-NEC and GB-ADC patients. A: Stage III–IV surgery versus surgery combined chemotherapy and or radiotherapy; B: GB-NEC versus GB- small cell NEC/GB-large cell NEC; C: GB-NEC versus GB-ADC; D: Stage III–IV GB-NEC versus GB-ADC. LCNC: Large cell neuroendocrine carcinoma; SCNC: Small cell neuroendocrine carcinoma; NEC: Neuroendocrine carcinoma; GB-NEC: Gallbladder NEC; GB-ADC: Gallbladder adenocarcinoma.